Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 2Neoplasms 2Fatigue 2Sleep Wake Disorders 1Recurrence 1Neoplasm Metastasis 1Hematologic Neoplasms 1Depression 1Brain Neoplasms 1Anxiety Disorders 1

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 25Rituximab 20pomalidomide 18Lenalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 12carfilzomib 11Temozolomide 11Injections 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Cisplatin 9Bortezomib 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8obinutuzumab 7cemiplimab 7Drug Therapy 7Carboplatin 7zanubrutinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × Methylphenidate × 1 year × Clear all
NCT03525873 2026-04-15

A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy

M.D. Anderson Cancer Center

Phase 3 Active not recruiting
212 enrolled

Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡